Company intelligence / Profile preview

Forcefield Ventures

London, United Kingdomin.marketscreener.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Forcefield Therapeutics is developing first-in-class biologic therapies to protect heart function by preventing the loss of cardiomyocytes after myocardial infarction. Their lead programs are in preclinical development, with strong IP protection and significant investment from Syncona and Roche Venture Fund. No clinical results have been reported yet.

Therapeutic areas: Cardiovascular
Modalities: ProteinBiologic
Industry: Biotech

Drug pipeline

1 asset

META-001-PH

Pre-clinical

Indications: Primary Hyperoxaluria

Partnerships

Syncona Investment Management Ltd.Roche Venture Fund

Beyond the preview

Go deeper on Forcefield Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forcefield Ventures.

Explore the full profile